Company profile
Kardigan, Inc.
NASDAQ:KARDBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DANICAMTIV | phase3 | — | 3 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07210723 | phase2_3 | recruiting | 2026-02-13 | 2027-09-01 | Kardigan, Inc. | A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy |
| NCT07771465 | phase3 | recruiting | 2026-08-26 | 2032-11-01 | Kardigan, Inc. | A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy |
| NCT06864104 | phase2 | completed | 2025-04-10 | 2026-01-12 | Kardigan, Inc. | A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL) |
| NCT07001800 | phase2_3 | recruiting | 2025-06-27 | 2028-08-31 | Kardigan, Inc. | Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study |
| NCT07511361 | phase2 | recruiting | 2026-06-23 | 2026-12-01 | Kardigan, Inc. | Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension |
FDA applications (0)
No records yet.